$6.70
2.60% yesterday
Nasdaq, Apr 11, 10:00 pm CET
ISIN
US0887861088
Symbol
BCYC
Sector
Industry

Bicycle Therapeutics Plc Target price 2025 - Analyst rating & recommendation

Bicycle Therapeutics Plc Classifications & Recommendation:

Buy
80%
Hold
20%

Bicycle Therapeutics Plc Price Target

Target Price $29.85
Price $6.70
Potential
Number of Estimates 13
13 Analysts have issued a price target Bicycle Therapeutics Plc 2026 . The average Bicycle Therapeutics Plc target price is $29.85. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 12 Analysts recommend Bicycle Therapeutics Plc to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Bicycle Therapeutics Plc stock has an average upside potential 2026 of . Most analysts recommend the Bicycle Therapeutics Plc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 35.29 32.67
30.32% 7.42%
EBITDA Margin -695.07% -801.33%
9.97% 15.29%
Net Margin -569.47% -710.20%
56.22% 24.71%

15 Analysts have issued a sales forecast Bicycle Therapeutics Plc 2025 . The average Bicycle Therapeutics Plc sales estimate is

$32.7m
Unlock
. This is
7.36% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$60.0m 70.12%
Unlock
, the lowest is
$14.8m 57.95%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $35.3m 30.32%
2025
$32.7m 7.42%
Unlock
2026
$34.2m 4.70%
Unlock
2027
$93.0m 171.79%
Unlock
2028
$276m 196.43%
Unlock
2029
$603m 118.70%
Unlock

3 Analysts have issued an Bicycle Therapeutics Plc EBITDA forecast 2025. The average Bicycle Therapeutics Plc EBITDA estimate is

$-262m
Unlock
. This is
6.77% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-228m 6.98%
Unlock
, the lowest is
$-319m 29.93%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-245m 17.32%
2025
$-262m 6.74%
Unlock
2026
$-344m 31.39%
Unlock
2027
$-376m 9.44%
Unlock
2028
$-450m 19.42%
Unlock
2029
$92.8m 120.65%
Unlock

EBITDA Margin

2024 -695.07% 9.97%
2025
-801.33% 15.29%
Unlock
2026
-1,005.62% 25.49%
Unlock
2027
-404.92% 59.73%
Unlock
2028
-163.13% 59.71%
Unlock
2029
15.40% 109.44%
Unlock

6 Bicycle Therapeutics Plc Analysts have issued a net profit forecast 2025. The average Bicycle Therapeutics Plc net profit estimate is

$-232m
Unlock
. This is
16.67% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-192m 3.47%
Unlock
, the lowest is
$-265m 33.33%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-201m 42.94%
2025
$-232m 15.46%
Unlock
2026
$-273m 17.62%
Unlock
2027
$-236m 13.41%
Unlock
2028
$-96.0m 59.38%
Unlock
2029
$113m 217.27%
Unlock

Net Margin

2024 -569.47% 56.22%
2025
-710.20% 24.71%
Unlock
2026
-797.82% 12.34%
Unlock
2027
-254.17% 68.14%
Unlock
2028
-34.83% 86.30%
Unlock
2029
18.68% 153.63%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.91 -3.36
42.94% 15.46%
P/E negative
EV/Sales negative

6 Analysts have issued a Bicycle Therapeutics Plc forecast for earnings per share. The average Bicycle Therapeutics Plc EPS is

$-3.36
Unlock
. This is
16.67% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.78 3.47%
Unlock
, the lowest is
$-3.84 33.33%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.91 42.94%
2025
$-3.36 15.46%
Unlock
2026
$-3.95 17.56%
Unlock
2027
$-3.42 13.42%
Unlock
2028
$-1.39 59.36%
Unlock
2029
$1.63 217.27%
Unlock

P/E ratio

Current -2.33 47.17%
2025
-1.99 14.59%
Unlock
2026
-1.70 14.57%
Unlock
2027
-1.96 15.29%
Unlock
2028
-4.82 145.92%
Unlock
2029
4.11 185.27%
Unlock

Based on analysts' sales estimates for 2025, the Bicycle Therapeutics Plc stock is valued at an EV/Sales of

-12.47
Unlock
and an P/S ratio of
14.16
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -11.55 164.74%
2025
-12.47 7.94%
Unlock
2026
-11.91 4.49%
Unlock
2027
-4.38 63.21%
Unlock
2028
-1.48 66.26%
Unlock
2029
-0.68 54.27%
Unlock

P/S ratio

Current 13.12 63.18%
2025
14.16 7.95%
Unlock
2026
13.53 4.49%
Unlock
2027
4.98 63.21%
Unlock
2028
1.68 66.26%
Unlock
2029
0.77 54.28%
Unlock

Current Bicycle Therapeutics Plc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Needham
Locked
Locked
Locked Apr 09 2025
Needham
Locked
Locked
Locked Mar 11 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 26 2025
Citizens Capital Markets
Locked
Locked
Locked Feb 26 2025
Needham
Locked
Locked
Locked Feb 26 2025
Stephens & Co.
Locked
Locked
Locked Jan 22 2025
Needham
Locked
Locked
Locked Jan 13 2025
Analyst Rating Date
Locked
Needham:
Locked
Locked
Apr 09 2025
Locked
Needham:
Locked
Locked
Mar 11 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 26 2025
Locked
Citizens Capital Markets:
Locked
Locked
Feb 26 2025
Locked
Needham:
Locked
Locked
Feb 26 2025
Locked
Stephens & Co.:
Locked
Locked
Jan 22 2025
Locked
Needham:
Locked
Locked
Jan 13 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today